Company Overview: Inovio


Industry News

21 Sep

Inovio dMAb™ Constructs Shrink Prostate Tumors and Protect Against Lethal Antibiotic-Resistant Bacterial Infection In Preclinical Studies

PLYMOUTH MEETING, Pa., Sept. 21, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that the development of its DNA-based monoclonal antibody program received a boost from two peer-reviewed scientific papers that demonstrate their impact on prostate tumors and in preventing infection from a pneumonia-causing bacteria in preclinical...

Read more

11 Sep

Inovio’s Cancer Immunotherapy (INO-5150) Slowed PSA Rise and Significantly Increased PSA Doubling Times In Patients with Recurrent Prostate Cancer

PLYMOUTH MEETING, Pa., Sept. 11, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO), today announced that an interim data analysis showed that its INO-5150 cancer immunotherapy product generated antigen-specific CD8+ killer T cell responses measured in peripheral blood from subjects with biochemically recurrent prostate cancer. The immunology results demonstrate...

Read more

23 Aug

Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences

PLYMOUTH MEETING, Pa., Aug. 23, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that the Company will participate in the following upcoming investment conferences: Citi’s 12th Annual Biotech Conference Panel Discussion: I/O Beyond PD-1: Opportunities & Challenges Dr. J. Joseph Kim, President & CEO 3:00 PM ET, September...

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address